Technology commercialisation company BTG will invest in Senexis, a biotechnology company that will develop treatments for ageing-related diseases such as Alzheimer's, Parkinson's and Huntington's.
Senexis, based at the University of Manchester Institute of Science and Technology, has raised £1.4 million from BTG and Catalyst BioMedica Limited to finance its research.
Register to continue
Why register?
- Registration is free and only takes a moment
- Once registered, you can read 3 articles a month
- Sign up for our newsletter
Subscribe
Or subscribe for unlimited access to:
- Unlimited access to news, views, insights & reviews
- Digital editions
- Digital access to THE’s university and college rankings analysis
Already registered or a current subscriber?
Please or to read this article.